Literature DB >> 11294012

Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.

C A Isaza1, J Henao, A M López, R Cacabelos.   

Abstract

Cytochrome P450 2D6 monooxygenase metabolizes several commonly used drugs, particularly psychotropics and cardiovascular agents. The gene that encodes this isoenzyme is highly polymorphic, with 1-10% of the population carrying mutations that produce an inactive enzyme, and 1-29% of individuals who possess additional copies of functional CYP2D6 genes. The genotypic features of the CYP2D6 gene have already been studied in many ethnic groups; however, the genetic characteristics of this enzyme are unknown in the Colombian population. The allelic variants and mutations of this polymorphic isoenzyme are the main cause of interindividual and interethnic differences in the therapeutic efficacy and adverse effects at standard doses of drugs metabolized by the products of the CYP2D6 gene. In the present study we have isolated, sequenced and genotyped the CYP2D6 gene in the Colombian population. The distribution of allelic frequencies of 10 alleles associated with normal, diminished or increased CYP2D6 activity has been studied in 121 healthy volunteers. The commonest alleles detected in the Colombian people were the functional alleles *1 (38.8%) and *2 (37%). Among the seven nonfunctional alleles studied in our sample, we found frequencies of 19.4%, 1.6%, 1.2% and 0.8%, for the *4, *17, *3 and *5 alleles, respectively. The alleles *6, *7 and *8 could not be identified in any of the subjects studied. The frequency of the duplicate allele was 1.2%. In this Colombian sample, 91.7% of the individuals were normal metabolizers (EM), 6.6% were poor metabolizers (PM), and 1.7% were ultrarapid metabolizers (UM). These results show that the allelic distribution of the CYP2D6 gene in the Colombian population of mestizo-prevalent subjects is compatible with the genomic assembly of the constitutive tri-ethnic origin of this Latin American country.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11294012     DOI: 10.1358/mf.2000.22.9.802286

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  16 in total

1.  Identification of CYP2D6 impaired functional alleles in Mexican Americans.

Authors:  Huai-Rong Luo; Andrea Gaedigk; Vasileios Aloumanis; Yu-Jui Yvonne Wan
Journal:  Eur J Clin Pharmacol       Date:  2005-11-08       Impact factor: 2.953

2.  CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.

Authors:  Marisol López; Jorge Guerrero; Helgi Jung-Cook; María Elisa Alonso
Journal:  Eur J Clin Pharmacol       Date:  2005-10-26       Impact factor: 2.953

Review 3.  Pharmacogenomics and therapeutic prospects in dementia.

Authors:  Ramón Cacabelos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

4.  High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies.

Authors:  M E G Naranjo; F de Andrés; A Delgado; J Cobaleda; E M Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2016-06-07       Impact factor: 3.550

5.  CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population.

Authors:  Pedro Dorado; Natalia Heras; Esther Machín; Francisco Hernández; Enrique Teran; Adrián Llerena
Journal:  Eur J Clin Pharmacol       Date:  2011-11-15       Impact factor: 2.953

Review 6.  Genomics and pharmacogenomics of schizophrenia.

Authors:  Ramón Cacabelos; Rocío Martínez-Bouza
Journal:  CNS Neurosci Ther       Date:  2010-08-16       Impact factor: 5.243

7.  Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.

Authors:  Alison Fohner; LeeAnna I Muzquiz; Melissa A Austin; Andrea Gaedigk; Adam Gordon; Timothy Thornton; Mark J Rieder; Mark A Pershouse; Elizabeth A Putnam; Kevin Howlett; Patrick Beatty; Kenneth E Thummel; Erica L Woodahl
Journal:  Pharmacogenet Genomics       Date:  2013-08       Impact factor: 2.089

Review 8.  Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

Authors:  Ramón Cacabelos
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

9.  Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico.

Authors:  Joel Salazar-Flores; Luis A Torres-Reyes; Gabriela Martínez-Cortés; Rodrigo Rubi-Castellanos; Martha Sosa-Macías; José F Muñoz-Valle; César González-González; Angélica Ramírez; Raquel Román; José L Méndez; Andrés Barrera; Alfredo Torres; Rafael Medina; Héctor Rangel-Villalobos
Journal:  Genet Test Mol Biomarkers       Date:  2012-08-22

10.  Frequencies of 23 functionally significant variant alleles related with metabolism of antineoplastic drugs in the chilean population: comparison with caucasian and asian populations.

Authors:  Angela Roco; Luis Quiñones; José A G Agúndez; Elena García-Martín; Valentina Squicciarini; Carla Miranda; Joselyn Garay; Nancy Farfán; Iván Saavedra; Dante Cáceres; Carol Ibarra; Nelson Varela
Journal:  Front Genet       Date:  2012-11-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.